The number of cannabidiol-based pharmaceutical products in the pipeline continues to grow, with the US Food and Drug Administration (FDA) recently granting yet another orphan drug designation for CBD.

The agency’s orphan drug programme is intended to encourage development of treatments for rare ailments affecting fewer than 200,000 people in the US (termed “orphan diseases”) or in other circumstances where it is unlikely that the cost of development will be recovered.

Created by the 1983 Orphan Drug Act, the designation does not permit products to be sold – an FDA marketing approval is still required for that – but it does allow manufacturers to benefit from tax breaks, reduced fees and other financial advantages, such as seven years’ protection from competition.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Request a free sample of this report:

“ CBD treatments on the way as FDA grants 20th ‘orphan drug’ designation ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ CBD treatments on the way as FDA grants 20th ‘orphan drug’ designation ”






      The number of cannabidiol-based pharmaceutical products in the pipeline continues to grow, with the US Food and Drug Administration (FDA) recently granting yet another orphan drug designation for CBD.

      The agency’s orphan drug programme is intended to encourage development of treatments for rare ailments affecting fewer than 200,000 people in the US (termed “orphan diseases”) or in other circumstances where it is unlikely that the cost of development will be recovered.

      Created by the 1983 Orphan Drug Act, the designation does not permit products to be sold – an FDA marketing approval is still required for that – but it does allow manufacturers to benefit from tax breaks, reduced fees and other financial advantages, such as seven years’ protection from competition.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik